Genzyme multiple sclerosis drugs

Genzyme continues to build the large late-stage data package for teriflunomide, an oral multiple sclerosis drug that the company and its

Genzyme Corp has presented more promising data on its investigational multiple sclerosis treatment alemtuzumab, a drug which played a

A multiple-sclerosis drug that was at the center of Sanofi SA's $20 billion takeover battle for Genzyme Corp. three years ago was approved

European regulators Tuesday put their stamp of approval on Genzyme's multiple sclerosis drug candidate Lemtrada, giving the Cambridge

Sanofi Genzyme to treat relapsing forms of multiple sclerosis (MS). The Food and Drug Administration (FDA) originally approved the drug's active ingredient

An injectable multiple sclerosis drug developed by Cambridge biotech giant Genzyme was made available to patients in the U.S. for the first

multiple sclerosis drug. Genzyme's shareholders did not think that the $20 billion offer reflected the future upside of Lemtrada. In an effort to keep the

treatment of active, relapsing multiple sclerosis (MS). Administration Genzyme's Lemtrada approved in Argentina for treatment of multiple sclerosis

The U.S. Food and Drug Administration (FDA) has approved a Genzyme drug for patients with relapsing forms of multiple sclerosis (MS), the company announced.